Ardelyx (ARDX) Current Assets (2013 - 2026)
Ardelyx's (ARDX) quarterly Current Assets came in at $381.9 million in Q1 2026, up 22.12% YoY from $312.7 million in Q1 2025, and little changed on a QoQ basis from $382.3 million in Q4 2025.
Ardelyx (ARDX) Current Assets (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Current Assets data on file, last reported at $381.9 million in Q1 2026.
- Quarterly Current Assets rose 22.12% year-over-year to $381.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $381.9 million (up 22.12% YoY) and the FY2025 annual result came in at $382.3 million, up 7.26% from the prior year.
- Current Assets steadied at $381.9 million in Q1 2026, from $382.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $382.3 million in Q4 2025 to a low of $114.1 million in Q2 2022.
- A 5-year average of $251.5 million and a median of $257.9 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets sank 44.38% — and 2023, when it jumped 101.22%.
- Tracing ARDX's Current Assets over 5 years: stood at $153.6 million in 2022, then soared by 60.23% to $246.1 million in 2023, then soared by 44.83% to $356.5 million in 2024, then increased by 7.26% to $382.3 million in 2025, then retreated by 0.12% to $381.9 million in 2026.
- The last three Current Assets figures came in at $381.9 million (Q1 2026), $382.3 million (Q4 2025), and $368.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 441.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 441.93 Mn |
| Mar 31, 2026 | 381.87 Mn |
| Dec 31, 2025 | 382.32 Mn |
| Sep 30, 2025 | 367.99 Mn |
| Jun 30, 2025 | 351.57 Mn |
| Mar 31, 2025 | 312.69 Mn |
| Dec 31, 2024 | 356.45 Mn |
| Sep 30, 2024 | 284.10 Mn |
| Jun 30, 2024 | 263.02 Mn |
| Mar 31, 2024 | 257.94 Mn |
| Dec 31, 2023 | 246.11 Mn |
| Sep 30, 2023 | 241.22 Mn |
| Jun 30, 2023 | 162.12 Mn |
| Mar 31, 2023 | 167.05 Mn |
| Dec 31, 2022 | 153.60 Mn |
| Sep 30, 2022 | 119.88 Mn |
| Jun 30, 2022 | 114.11 Mn |
| Mar 31, 2022 | 114.23 Mn |
| Dec 31, 2021 | 133.65 Mn |
| Sep 30, 2021 | 153.38 Mn |